VRCA Verrica Pharmaceuticals

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 8:45 a.m. ET.

Participants may access a live webcast of the event through the following link:

.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at . The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit .

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis

Chief Financial Officer

484.453.3300 ext. 103

William Windham

Solebury Trout

646.378.2946

Media:

Zara Lockshin

Solebury Trout

646.378.2960



EN
06/04/2021

Underlying

VRCAVerrica Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verrica Pharmaceuticals

 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract...

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data of VP-315, Verrica’s n...

April 9, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virt...

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026...

April 6, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and t...

March 11, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fi...

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December ...

March 5, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Hea...

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday,...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch